Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

Objective The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4+ T-cell counts and immune activation in these patients. Design Double-blind, placebo-controlled, randomized trial. Methods Major inclusion criteria were 1. CD4+ T-cell count <350 cells/μL while at least two years on cART or CD4+ T-cell count <200 cells/μL while at least one year on cART, and 2. viral suppression for at least the previous 6 months. HIV-infected patients were randomized to add maraviroc (41 patients) or placebo (44 patients) to their cART regimen for 48 weeks. Changes in CD4+ T-cell counts (primary endpoint) and other immunological parameters were modeled using linear mixed effects models. Results No significant differences for the modelled increase in CD4+ T-cell count (placebo 15.3 CD4+ T cells/μL (95% confidence interval (CI) [1.0, 29.5] versus maraviroc arm 22.9 CD4+ T cells/μL (95% CI [7.4, 38.5] p = 0.51) or alterations in the expression of markers for T-cell activation, proliferation and microbial translocation were found between the arms. However, maraviroc intensification did increase the percentage of CCR5 expressing CD4+ and CD8+ T-cells, and the plasma levels of the CCR5 ligand MIP-1β. In contrast, the percentage of ex-vivo apoptotic CD8+ and CD4+ T-cells decreased in the maraviroc arm. Conclusions Maraviroc intensification of cART did not increase CD4+ T-cell restoration or decrease immune activation as compared to placebo. However, ex-vivo T-cell apoptosis was decreased in the maraviroc arm. Trial Registration ClinicalTrials.gov NCT00875368

[1]  M. Martínez-Bonet,et al.  Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects. , 2014, The Journal of infectious diseases.

[2]  G. d’Ettorre,et al.  Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial , 2013, PloS one.

[3]  B. Autran,et al.  Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals. , 2013, Blood.

[4]  M. Lederman,et al.  The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. , 2013, Blood.

[5]  M. Plana,et al.  In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. , 2013, The Journal of antimicrobial chemotherapy.

[6]  L. Cuzin,et al.  Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration: MARIMUNO-ANRS 145 Study , 2012, Journal of acquired immune deficiency syndromes.

[7]  M. Nelson,et al.  CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection , 2012, Molecular medicine.

[8]  J. Eliaou,et al.  The intensity of immune activation is linked to the level of 
CCR5 expression in human immunodeficiency virus type 
1‐infected persons , 2012, Immunology.

[9]  J. Mellors,et al.  A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. , 2012, The Journal of infectious diseases.

[10]  J. Hoxie,et al.  Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. , 2012, The New England journal of medicine.

[11]  R. Paredes,et al.  Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  A. Wensing,et al.  Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort , 2012, AIDS.

[13]  J. Zamora,et al.  Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected , 2011, PloS one.

[14]  A. Wensing,et al.  European guidelines on the clinical management of HIV-1 tropism testing. , 2011, The Lancet. Infectious diseases.

[15]  J. Borghans,et al.  Decreased Thymic Output Accounts for Decreased Naive T Cell Numbers in Children with Down Syndrome , 2011, The Journal of Immunology.

[16]  T. Wilkin,et al.  The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients , 2010, HIV clinical trials.

[17]  D. Cooper,et al.  A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection. , 2010, AIDS research and human retroviruses.

[18]  D. Cooper,et al.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. , 2010, The Journal of infectious diseases.

[19]  R. Eng,et al.  Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD 4 recovery , 2009 .

[20]  Jeffrey N. Martin,et al.  Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Thiel,et al.  Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. , 2009, Blood.

[22]  S. Mummidi,et al.  CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation1 , 2009, The Journal of Immunology.

[23]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[24]  David Krason,et al.  Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases , 2008, Journal of acquired immune deficiency syndromes.

[25]  F. Ceccherini‐Silberstein,et al.  Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. , 2008, The Journal of infectious diseases.

[26]  A. Westfall,et al.  Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients With Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.

[27]  D. Richman,et al.  CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals , 2008, Nature Medicine.

[28]  J. Clot,et al.  The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5 , 2008, AIDS.

[29]  H. Putter,et al.  CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms , 2007, Circulation.

[30]  J. Borghans,et al.  Quantification of T‐cell dynamics: from telomeres to DNA labeling , 2007, Immunological reviews.

[31]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[32]  J. McCune,et al.  Direct measurement of T-cell receptor repertoire diversity with AmpliCot , 2006, Nature Methods.

[33]  E. Fish,et al.  CCL5-CCR5-mediated Apoptosis in T Cells , 2006, Journal of Biological Chemistry.

[34]  B. Yip,et al.  Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy , 2005, Journal of acquired immune deficiency syndromes.

[35]  Caroline A Sabin,et al.  Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. , 2004, The Journal of infectious diseases.

[36]  Peter Hunt,et al.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.

[37]  L. Bluck.  STABLE ISOTOPES IN HUMAN NUTRITION , 2004 .

[38]  M. Lederman,et al.  Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy , 2003, AIDS.

[39]  Hanneke Schuitemaker,et al.  Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation , 2003, AIDS.

[40]  O. Kirk,et al.  Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study , 2003, HIV medicine.

[41]  J. Corbeil,et al.  Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. , 2003, The Journal of infectious diseases.

[42]  Jeffrey N. Martin,et al.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.

[43]  S. Moreno,et al.  Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  C. Payá,et al.  CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells , 2002, AIDS.

[45]  L. Perrin,et al.  Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection , 2002, AIDS.

[46]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[47]  M. Kazatchkine,et al.  Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. , 2001, The Journal of infectious diseases.

[48]  H. Schuitemaker,et al.  T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock , 2000, Nature Immunology.

[49]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[50]  M. Hellerstein,et al.  Measurement of T-cell kinetics: recent methodologic advances. , 1999, Immunology today.

[51]  Rob J. De Boer,et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.

[52]  R. Doms,et al.  A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains , 1996, Journal of virology.

[53]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[54]  F Miedema,et al.  T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). , 2000, Blood.